SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Johnsson E) "

Sökning: WFRF:(Johnsson E)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Abazov, V. M., et al. (författare)
  • The upgraded DO detector
  • 2006
  • Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - 0168-9002 .- 1872-9576. ; 565:2, s. 463-537
  • Tidskriftsartikel (refereegranskat)abstract
    • The DO experiment enjoyed a very successful data-collection run at the Fermilab Tevatron collider between 1992 and 1996. Since then, the detector has been upgraded to take advantage of improvements to the Tevatron and to enhance its physics capabilities. We describe the new elements of the detector, including the silicon microstrip tracker, central fiber tracker, solenoidal magnet, preshower detectors, forward muon detector, and forward proton detector. The uranium/liquid -argon calorimeters and central muon detector, remaining from Run 1, are discussed briefly. We also present the associated electronics, triggering, and data acquisition systems, along with the design and implementation of software specific to DO.
  •  
2.
  • Abazov, V. M., et al. (författare)
  • Measurement of the t(t)over-bar production cross section in p(p)over-bar collisions at root s=1.96 TeV using secondary vertex b tagging
  • 2006
  • Ingår i: Physical Review D - Particles, Fields, Gravitation and Cosmology. - 1550-7998 .- 1550-2368. ; 74:11, s. 112004-
  • Tidskriftsartikel (refereegranskat)abstract
    • We report a new measurement of the t (t) over bar production cross section in p (beta) over bar collisions at a center-of-mass energy of 1.96 TeV using events with one charged lepton (electron or muon), missing transverse energy, and jets. Using 425 pb(-1) of data collected using the D0 detector at the Fermilab Tevatron Collider, and enhancing the t (t) over bar content of the sample by tagging b jets with a secondary vertex tagging algorithm, the t (t) over bar production cross section is measured to be sigma(p (t) over bar -> t (t) over bar +X)=6.6 +/- 0.9(stat+syst) +/- 0.4(lum) pb. This cross section is the most precise D0 measurement to date for t (t) over bar production and is in good agreement with standard model expectations.
  •  
3.
  • Vikgren, Jenny, 1957, et al. (författare)
  • Visual and Quantitative Evaluation of Emphysema: A Case-Control Study of 1111 Participants in the Pilot Swedish CArdioPulmonary BioImage Study (SCAPIS)
  • 2020
  • Ingår i: Academic Radiology. - : ELSEVIER SCIENCE INC. - 1076-6332 .- 1878-4046. ; 27:5, s. 636-643
  • Tidskriftsartikel (refereegranskat)abstract
    • Rationale and Objectives: Emphysema is a hallmark of chronic obstructive pulmonary disease. The primary aim of this study was to investigate inter- and intraobserver agreement of visual assessment of mild emphysema in low-dose multidetector computed tomography of subjects in the pilot SCAPIS in order to certify consistent detection of mild emphysema. The secondary aim was to investigate the performance of quantitative densitometric measurements in the cohort. Materials and Methods: Participants with emphysema (n = 100, 56 males and 44 females) reported in the electronic case report form of pilot SCAPIS and 100 matched controls (gender, age, height, and weight) without emphysema were included. To assess interobserver variability the randomized examinations were evaluated by two thoracic radiologists. For intraobserver variability three radiologists re-evaluated randomized examinations which they originally evaluated. The results were evaluated statistically by Krippendorff's α. The dataset was also assessed quantitively for % lung attenuation value −950 HU (LAV950), mean lung density and total lung volume by commercially available software. Results: Emphysema was visually scored as mild and Krippendorff's α was ≥0.8 for both the inter- and intraobserver agreement regarding presence of emphysema and approaching 0.8 regarding presence and extent of emphysema by location in the upper lobes. Mean LAV950 was not different between the emphysematous and the nonemphysematous participants; 8.3% and 8.4%, respectively. Conclusion: The inter- and intraobserver agreement for visual detection of mild emphysema in low-dose multidetector computed tomography was good. Surprisingly, quantitative analysis could not reliably identify participants with mild emphysema, which hampers the use of automatic evaluation. © 2019 The Association of University Radiologists
  •  
4.
  • Barillot, T., et al. (författare)
  • Angular asymmetry and attosecond time delay from the giant plasmon resonance in C-60 photoionization
  • 2015
  • Ingår i: Physical Review A (Atomic, Molecular and Optical Physics). - : American Physical Society. - 1050-2947 .- 1094-1622. ; 91:3
  • Tidskriftsartikel (refereegranskat)abstract
    • This combined experimental and theoretical study demonstrates that the surface plasmon resonance in C-60 alters the valence photoemission quantum phase, resulting in strong effects in the photoelectron angular distribution and emission time delay. Electron momentum imaging spectroscopy is used to measure the photoelectron angular distribution asymmetry parameter that agrees well with our calculations from the time-dependent local density approximation (TDLDA). Significant structure in the valence photoemission time delay is simultaneously calculated by TDLDA over the plasmon active energies. Results reveal a unified spatial and temporal asymmetry pattern driven by the plasmon resonance and offer a sensitive probe of electron correlation. A semiclassical approach facilitates further insights into this link that can be generalized and applied to other molecular systems and nanometer-sized metallic materials exhibiting plasmon resonances.
  •  
5.
  • Enblom, A, et al. (författare)
  • Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea - a randomized controlled study.
  • 2012
  • Ingår i: Annals of oncology. - : Oxford University Press. - 1569-8041. ; 23:5, s. 1353-1361
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: It is not known if verum (real) acupuncture is effective for nausea and vomiting (emesis) during radiotherapy. PATIENTS AND METHODS: We randomly treated 215 blinded cancer patients with verum: penetrating 'deqi' creating acupuncture (n = 109) or non-penetrating sham needles (n = 106) two to three times per week. The patients documented emesis daily during the radiotherapy period. Primary end point was the number of patients with at least one episode of nausea. RESULTS: In the verum and the sham acupuncture group, 70% and 62% experienced nausea at least once during the radiotherapy period (relative risk 1.1, 95% CI 0.9-1.4) for a mean number of 10.1 and 8.7 days. Twenty five percent and 28% vomited, and 42% and 37% used antiemetic drugs at least once, respectively. Ninety-five percent in the verum acupuncture group and 96% in the sham acupuncture group believed that the treatment had been effective against nausea. In both groups, 67% experienced positive effects on relaxation, mood, sleep or pain reduction and 89% wished to receive the treatment again. CONCLUSION: Acupuncture creating deqi is not more effective than sham in radiotherapy-induced nausea, but in this study, nearly all patients in both groups experienced that the treatment was effective for nausea.
  •  
6.
  • Hagman, H., et al. (författare)
  • A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer : the Nordic ACT2 trial
  • 2016
  • Ingår i: Annals of Oncology. - : OXFORD UNIV PRESS. - 0923-7534 .- 1569-8041. ; 27:1, s. 140-147
  • Tidskriftsartikel (refereegranskat)abstract
    • Maintenance treatment (mt) with bevacizumab (bev) +/- erlotinib (erlo) has modest effect after induction chemotherapy in metastatic colorectal cancer (mCRC). We hypothesized the efficacy of erlo to be dependent on KRAS mutational status and investigated this by exploring mt strategies with bev +/- erlo and low-dose capecitabine (cap). Included patients had mCRC scheduled for first-line therapy, Eastern Cooperative Oncology Group (ECOG) 0-1 and no major comorbidities. Treatment with XELOX/FOLFOX or XELIRI/FOLFIRI + bev was given for 18 weeks. After induction, patients without progression were eligible for randomization to mt; KRAS wild-type (wt) patients were randomized to bev +/- erlo (arms wt-BE, N = 36 versus wt-B, N = 35), KRAS mutated (mut) patients were randomized to bev or metronomic cap (arms mut-B, N = 34 versus mut-C, N = 33). Primary end point was progression-free survival (PFS) rate (PFSr) at 3 months after start of mt. A pooled analysis of KRAS wt patients from the previous ACT study was performed. We included 233 patients. Median age was 64 years, 62% male, 68% ECOG 0, 52% with primary tumor in situ. A total of 138 patients started mt after randomization. PFSr was 64.7% versus 63.6% in wt-B versus wt-BE, P = 1.000; and 75% versus 66.7% in mut-B versus mut-C, P = 0.579, with no significant difference in median PFS and overall survival (OS). In the pooled cohort, median PFS was 3.7 months in wt-B (N = 64) and 5.7 months in wt-BE (N = 62) (hazard ratios 1.03, 95% confidence interval 0.70-1.50, P = 0.867). The frequency of any grade 3/4 toxicities during mt was: 28%/58%/18%/15% (wt-B/wt-BE/mut-B/mut-C). Addition of erlo to bev as mt in KRAS wt mCRC did not significantly improve PFS or OS, but it did increase toxicity. KRAS status does not seem to influence the outcome of treatment with erlotinib. Metronomic cap warrants further investigation in mt strategies, given our explorative results. NCT01229813.
  •  
7.
  • Persson, Jan, et al. (författare)
  • Fully covered stents are similar to semi-covered stents with regard to migration in palliative treatment of malignant strictures of the esophagus and gastric cardia : results of a randomized controlled trial.
  • 2017
  • Ingår i: Surgical Endoscopy. - 0930-2794 .- 1432-2218. ; 31:10, s. 4025-4033
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: Stent migration is a significant clinical problem in palliation of malignant strictures in the esophagus and gastro-esophageal junction (GEJ). We have compared a newer design of a fully-covered stent to a widely used semi-covered stent using migration >20 mm as the primary outcome variable. Effects on dysphagia, quality of life (QoL) and re-intervention frequency were also investigated.METHODS: Patients with dysphagia due to non-curable esophagus/GEJ cancer were randomized to receive either a more recent design of a fully-covered stent (n = 48) or a conventional semi-covered stent (n = 47). Chest x-ray, dysphagia and QoL were studied at baseline, one week, four weeks and three months thereafter.RESULTS: There were no significant differences either in stent migration distance or in the migration frequency. Stent migration during the total study period occurred in 37.2 % in the semi-covered group compared to 20.0 % for the fully-covered group. Dysphagia was measured with Watson and Ogilvie scores and with the dysphagia module in the QoL scale (QLQ-OG25). On average, there was a tendency to better dysphagia relief for the fully-covered design as scored with the two latter dysphagia instruments (p= 0.081 and p= 0.067) at three months and towards more re-interventions in the semi-covered group (p= 0.083).CONCLUSION: In spite of its somewhat lower intrinsic radial force, the fully-covered stent was comparable to the conventional semi-covered stent with regard to stent migration. The data further suggest a potential benefit of the fully-covered stent in improving dysphagia in patients with longer life expectancy.
  •  
8.
  • Polymeri, E., et al. (författare)
  • Deep learning-based quantification of PET/CT prostate gland uptake : association with overall survival
  • 2020
  • Ingår i: Clinical Physiology and Functional Imaging. - Chichester : Blackwell Publishing. - 1475-0961 .- 1475-097X. ; 40:2, s. 106-113
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: To validate a deep-learning (DL) algorithm for automated quantification of prostate cancer on positron emission tomography/computed tomography (PET/CT) and explore the potential of PET/CT measurements as prognostic biomarkers. Material and methods: Training of the DL-algorithm regarding prostate volume was performed on manually segmented CT images in 100 patients. Validation of the DL-algorithm was carried out in 45 patients with biopsy-proven hormone-naïve prostate cancer. The automated measurements of prostate volume were compared with manual measurements made independently by two observers. PET/CT measurements of tumour burden based on volume and SUV of abnormal voxels were calculated automatically. Voxels in the co-registered 18F-choline PET images above a standardized uptake value (SUV) of 2·65, and corresponding to the prostate as defined by the automated segmentation in the CT images, were defined as abnormal. Validation of abnormal voxels was performed by manual segmentation of radiotracer uptake. Agreement between algorithm and observers regarding prostate volume was analysed by Sørensen-Dice index (SDI). Associations between automatically based PET/CT biomarkers and age, prostate-specific antigen (PSA), Gleason score as well as overall survival were evaluated by a univariate Cox regression model. Results: The SDI between the automated and the manual volume segmentations was 0·78 and 0·79, respectively. Automated PET/CT measures reflecting total lesion uptake and the relation between volume of abnormal voxels and total prostate volume were significantly associated with overall survival (P = 0·02), whereas age, PSA, and Gleason score were not. Conclusion: Automated PET/CT biomarkers showed good agreement to manual measurements and were significantly associated with overall survival. © 2019 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine
  •  
9.
  • Tveit, Kjell Magne, et al. (författare)
  • Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study.
  • 2012
  • Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 1527-7755 .- 0732-183X. ; 30:15, s. 1755-1762
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSEThe NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC). The influence of KRAS mutation status on treatment outcome was also investigated. PATIENTS AND METHODSPatients were randomly assigned to receive either standard Nordic FLOX (arm A), cetuximab and FLOX (arm B), or cetuximab combined with intermittent FLOX (arm C). Primary end point was progression-free survival (PFS). Overall survival (OS), response rate, R0 resection rate, and safety were secondary end points.ResultsOf the 571 patients randomly assigned, 566 were evaluable in intention-to-treat (ITT) analyses. KRAS and BRAF mutation analyses were obtained in 498 (88%) and 457 patients (81%), respectively. KRAS mutations were present in 39% of the tumors; 12% of tumors had BRAF mutations. The presence of BRAF mutations was a strong negative prognostic factor. In the ITT population, median PFS was 7.9, 8.3, and 7.3 months for the three arms, respectively (not significantly different). OS was almost identical for the three groups (20.4, 19.7, 20.3 months, respectively), and confirmed response rates were 41%, 49%, and 47%, respectively. In patients with KRAS wild-type tumors, cetuximab did not provide any additional benefit compared with FLOX alone. In patients with KRAS mutations, no significant difference was detected, although a trend toward improved PFS was observed in arm B. The regimens were well tolerated. CONCLUSIONCetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (175)
konferensbidrag (40)
bokkapitel (10)
rapport (5)
forskningsöversikt (2)
annan publikation (1)
visa fler...
doktorsavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (193)
övrigt vetenskapligt (39)
populärvet., debatt m.m. (2)
Författare/redaktör
Johnsson, P. (43)
Johnsson, E (43)
Johnsson, A. (37)
Johnsson, Per (34)
L'Huillier, A. (19)
Lundell, L. (14)
visa fler...
L'Huillier, Anne (14)
Varju, K. (13)
Mauritsson, J. (13)
Ueda, K (12)
Fukuzawa, H. (12)
Lepine, F. (12)
Vrakking, M. J. J. (12)
Berglund, Mats (11)
Motomura, K. (10)
Nagaya, K. (10)
Linnarsson, S (9)
Leckner, Bo G, 1936 (9)
Johnsson, Filip, 196 ... (9)
Johnsson, Erik, 1966 (9)
Sansone, G. (9)
Turesson, I (8)
Ali, M (8)
Hansson, M (8)
Nilsson, B (8)
Nahi, H (8)
Gustafsson, E. (8)
Arnold, C. L. (8)
Gullberg, U (8)
Waage, A (8)
Andersson, Claes (8)
Mauritsson, Johan (8)
Johnsson, H. (8)
Lopez-Martens, R. (8)
Liu, X. J. (8)
Mondal, S. (8)
Tachibana, T. (8)
Matsunami, K. (8)
Johnsson, J. E. (8)
Gullberg, Urban (7)
Hemminki, K (7)
Weinhold, N (7)
Goldschmidt, H (7)
Mevel, E (7)
Nisoli, M. (7)
Yao, M (7)
Constant, E (7)
Kling, M. F. (7)
Fernebro, E (7)
Ghafur, O. (7)
visa färre...
Lärosäte
Lunds universitet (93)
Karolinska Institutet (58)
Göteborgs universitet (50)
Uppsala universitet (41)
Chalmers tekniska högskola (17)
Linköpings universitet (12)
visa fler...
Stockholms universitet (10)
Kungliga Tekniska Högskolan (9)
Malmö universitet (9)
Umeå universitet (4)
Linnéuniversitetet (2)
RISE (2)
Luleå tekniska universitet (1)
Örebro universitet (1)
Mittuniversitetet (1)
Södertörns högskola (1)
Högskolan i Halmstad (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (223)
Svenska (7)
Odefinierat språk (2)
Tyska (1)
Franska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (76)
Naturvetenskap (69)
Teknik (14)
Samhällsvetenskap (10)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy